中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
1期
72-73
,共2页
乳腺癌%免疫组化%微小RNA
乳腺癌%免疫組化%微小RNA
유선암%면역조화%미소RNA
breast cancer%immunohistochemistry%miRNA
目的：观察miR-340蛋白的表达在三阴乳腺癌（triple-negative breast cancer,TNBC）的发生，发展和转移中的作用。方法选择2006年1月～2012年12月在我院行乳腺癌根治的患者60例，根据免疫组织化学的雌激素受体（estrogen receptor, ER），孕激素受体（progesterone receptor, PR）和人表皮生长因子的受体（human epidermal growth factor receptor,HER-2）表达，分为三阴性乳腺癌(triple negative breast cancer,TNBC)33例和非TNBC 27例，同时选择同期乳腺癌癌旁组织15例，运用免疫组化检测miR-340蛋白的表达。结果癌旁组织的miR-340阳性表达率为73.33%，TNBC为51.52%，而非TNBC为29.63%，三组表达差异有统计学意义（χ2=7.671，P<0.05）。miR-340蛋白的表达在TNBC和非TNBC患者中与年龄，月经状态和肿瘤直径差异无统计学意义；而miR-340蛋白的表达与TNBC的临床分期和淋巴结是否转移具有明显的相关性(P<0.05)。结论 miR-340参与了TNBC的发生发展，可能成为TNBC治疗的目的基因之一。
目的：觀察miR-340蛋白的錶達在三陰乳腺癌（triple-negative breast cancer,TNBC）的髮生，髮展和轉移中的作用。方法選擇2006年1月～2012年12月在我院行乳腺癌根治的患者60例，根據免疫組織化學的雌激素受體（estrogen receptor, ER），孕激素受體（progesterone receptor, PR）和人錶皮生長因子的受體（human epidermal growth factor receptor,HER-2）錶達，分為三陰性乳腺癌(triple negative breast cancer,TNBC)33例和非TNBC 27例，同時選擇同期乳腺癌癌徬組織15例，運用免疫組化檢測miR-340蛋白的錶達。結果癌徬組織的miR-340暘性錶達率為73.33%，TNBC為51.52%，而非TNBC為29.63%，三組錶達差異有統計學意義（χ2=7.671，P<0.05）。miR-340蛋白的錶達在TNBC和非TNBC患者中與年齡，月經狀態和腫瘤直徑差異無統計學意義；而miR-340蛋白的錶達與TNBC的臨床分期和淋巴結是否轉移具有明顯的相關性(P<0.05)。結論 miR-340參與瞭TNBC的髮生髮展，可能成為TNBC治療的目的基因之一。
목적：관찰miR-340단백적표체재삼음유선암（triple-negative breast cancer,TNBC）적발생，발전화전이중적작용。방법선택2006년1월～2012년12월재아원행유선암근치적환자60례，근거면역조직화학적자격소수체（estrogen receptor, ER），잉격소수체（progesterone receptor, PR）화인표피생장인자적수체（human epidermal growth factor receptor,HER-2）표체，분위삼음성유선암(triple negative breast cancer,TNBC)33례화비TNBC 27례，동시선택동기유선암암방조직15례，운용면역조화검측miR-340단백적표체。결과암방조직적miR-340양성표체솔위73.33%，TNBC위51.52%，이비TNBC위29.63%，삼조표체차이유통계학의의（χ2=7.671，P<0.05）。miR-340단백적표체재TNBC화비TNBC환자중여년령，월경상태화종류직경차이무통계학의의；이miR-340단백적표체여TNBC적림상분기화림파결시부전이구유명현적상관성(P<0.05)。결론 miR-340삼여료TNBC적발생발전，가능성위TNBC치료적목적기인지일。
Objective To investigate the relationship among the expression of miR-340 protein, occurrence, development and metastasis in triple-negative breast cancer (TNBC). Method 60 patients with breast cancer, from January 2006 to December 2012, according to the immunohistochemistry expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER-2), were divided into TNBC (33 patients) and non-TNBC (27 patients), and the breast cancer tissues (15 patients) were also selected at the same period, and the expression of miR-340 protein were detected by the immunohistochemistry. Results The positive expression of miR-340 protein was 73.33%in adjacent tissues of breast cancer, 51.52%in TNBC, 29.63%non-TNBC, the expression differences of each group were statistically significant(χ2=7.671,P<0.05). The expression of miR-340 protein in TNBC and non-TNBC patients were no significant difference in age, menopausal status and tumor size;while there were obvious correlation among clinical stage, lymph node metastasis and protein expression of miR-340 in TNBC(P<0.05). Conclusion The gene of miR-340 involves in the occurrence, development and metastasis of TNBC, they would be one of the purposes gene therapy in TNBC.
